Scientific Program – ART/IVF/Infertility

Friday, November 13 & Saturday, November 14, 2026

Friday, November 13

08:30-10:00 ARTIFICIAL INTELLIGENCE (AI) HALL A
Capsule
Chairpersons Frank Broekmans, Netherlands
08:30-09:00

08:30
08:40
08:50

Debate: Any place for AI in ovulation induction

Yes: Konstantinos Dafopoulos, Greece
No: Charalampos Siristatidis Greece
Discussion

09:00-09:15

New developments in the use of AI for ovarian stimulation
Vasiliki A. Moragianni, USA

09:15-09:20

Discussion

09:20-09:35 Day 3 compared to day 5
Raoul Orvieto, Israel
09:35-09:40

Discussion

09:40-09:55 Deep learning versus manual morphology-based embryo selection in IVF: Results of the largest published RCT
Christos Venetis, Greece
09:55-10:00 Discussion

 

10:00-10:30 Coffee break, visit the exhibition, and e-poster viewing

 

10:30-12:00 SURPRISE ME WITH… UNEXPECTED SOLUTIONS… HALL A
Capsule Hot controversial clinical issues
Chairpersons Jacques Donnez, Belgium
Paul Pirtea, France
10:30-10:45

The surprising results of the optimal follicular size before trigger: What AI reveals?
Simon Hanassab, UK

10:45-10:50

Discussion

10:50-11:20

10:50
11:00
11:10

Debate: Stem cells or surgery for Asherman syndrome?

Operation, even in extreme cases – what are the limits? Ettore Cicinelli, Italy
Stem cells for endometrial regeneration: Xavier Santamaria,Spain
Discussion

11:20-11:35 Double trigger compared to IVM
Raoul Orvieto, Israel
11:35-11:40 Discussion
11:40-11:55 Istmocele: When to treat before a new pregnancy and when not
Ettore Cicinelli, Italy
11:55-12:00 Discussion

 

12:00-12:05 Change of session

 

12:05-12:30 PLENARY SESSION HALL A
Streamed to all halls
Capsule PCOS is the most common endocrinopathy that affect all phases of women’s life
Chairpersons Bart Fauser, Netherlands
Joop Laven, Netherlands
12:05-12:30 PCOS in OBGYN (overview of PCO in reproductive life, menopause, pregnancy etc)
Terhi Piltonen, Finland

 

12:30-12:35 Change of session

 

12:35-13:35

Industry supported session – Hall A
Industry supported session – Hall B

 

13:35-14:30 Lunch break, visit the exhibition,  and e-poster viewing

 

14:30-15:30 IMPLANTATION FAILURE HALL A
Capsule RIF: Aneuploidy is the main reason, while all other reasons are infrequent and correctable.
Chairpersons

Zion Ben Rafael, Israel
Edgardo Somigilana, Italy

14:30-14:40

Ethnic disparities in IVF success, implications to treatment personalization
Simon Hanassab, UK

14:40-14:45 Discussion
14:45-15:15

14:45
14:55
15:05

Debate: What is the origin of implantation failure?

Euploidy is crucial and is age-dependent: Paul Pirtea, France
Euploidy is not enough for implantation: Antonis Makrigiannakis, Greece
Discussion

15:15-15:25

Immunological factor – Endometrial profiling and LBR (RCT)
Efstratios Kolibianakis, Greece

15:25-15:30 Discussion

 

15:30-15:35 Change of session

 

15:35-17:00 SIMPLE LESS EXPENSIVE IVF? HALL A
Capsule Should we adopt more simple, affordable IVF and prevent expensive, additional unproven add-ons?
Chairpersons

Basil Tarlatzis, Greece

15:35-15:50

Modern IVF settings: is the cost rising while the chances are falling?
Norbert Gleicher, USA

15:50-15:55 Discussion
15:55-16:10

Low resources setting, high IVF results
Willem Ombelet, Belgium

16:10-16:15 Discussion
16:15-16:35

After how many IVF failures should we adopt add-ons?
Edgardo Somigliana, Italy

16:35-16:40 Discussion
16:40-16:55 Progestin-based ovarian stimulation vs, GnRh analogues
Paul Pirtea, France
16:55-17:00 Discussion

 

17:00-17:15 Coffee break, visit the exhibition, and e-poster viewing

 

17:15-18:30 MANAGEMENT OF UTERINE FIBROIDS HALL A
Capsule 

Fibroids that distort the uterine cavity are likely to affect fertility however the effect of non-cavity distorting intramural fibroids on fertility is still debated. Does their presence lower the chance of achieving a live birth?

Chairpersons 

Ettore Cicinelli, Italy
George L. Adonakis, Greece

17:15-17:35

17:15
17:20
17:25

Debate: Intramural fibroids should be enucleated before IVF

Yes: Nikolaos Vlachos, Greece
No: Antonis Makrigiannakis, Greece
Discussion

17:35-17:50

Hysteroscopic management of submucous fibroids: Techniques and limitations
Grigoris F. Grimbizis, Greece

17:50-17:55 Discussion
17:55-18:10

Which fibroids should be removed and how before IVF?
Angelos Daniilidis, Greece

18:10-18:15 Discussion
18:15-18:30 REAdMe – Fertility-limiting diseases of the pelvic organs and their influence on endometrial cavity receptivity
Michal Mára, Czech Republic

Saturday, November 14

08:30-10:00 PCOS  HALL A
Capsule It is important to get the new name promoted and implemented
Chairpersons Bart Fauser, Netherlands
Basil Tarlatzis, Greece
08:30-08:55

Name change: Patients perspective
Rachel Morman, UK

08:55-09:00 Discussion
00:00-09:25

Name change: The health care providers perspective
Terhi Piltonen, Finland

09:20-09:30 Discussion
09:30-09:55

Name Change: Dissemination of the new name
Joop Laven, Netherlands

09:55-10:00 Discussion

 

10:00-10:30  Coffee break, visit the exhibition, and e-poster viewing

 

10:30-12:00 PGT-A HALL A
Capsule An ASRM statement, grounded in over 30 years of experience and multiple randomized controlled trials demonstrating no clinical improvement in IVF outcomes with the use of PGT-A, nevertheless PGT-A sharply increase in utilization
Chairpersons Laura Rienzi, Italy
Norbert Gleicher, USA
10:30-10:45

Do we agree that all cases with Mosaicism can be transferred and should not be reported

10:45-10:50 Discussion
10:50-11:20

10:50
11:00
11:10

Debate: Claims of lower miscarriage rate and speed up of the time to pregnancy

Pro: This justifies the cost and utilization of PGT-A! Christos Venetis, Greece
Con: Only if we don’t trust the RCTs showing no effect of PGT-A? Mina Popovic, Spain
Discussion

11:20-11:35

Invasive vs Noninvasive PGT -A: From cell DNA to cell – free DNA
Dimitris Loutradis, Greece

11:35-11:40 Discussion
11:40-11:55

Why we decided to sue the PGT-A

11:55-12:00 Discussion

 

12:00-12:05 Change of session

 

12:05-12:30 PLENARY SESSION HALL A
Streamed to all halls
Capsule Epigenetics and reprogramming research in infertility and in utero development focuses on how DNA methylation, histone modification, and RNA interact during gametogenesis, early embryogenesis and placentation, disruption of which causes infertility and pregnancy complications
Chairpersons Rene Frydman, France
Mina Popovich, Spain
12:05-12:30

Epigenetics and reprogramming
David Monk, UK

 

13:35-14:30 Lunch break, visit the exhibition,  and e-poster viewing

 

13:30-15:00   Q&A HALL A
Capsule Experts’ views on controversial and unsolved clinical and laboratory questions
Chairpersons Zion Ben Rafael, Israel
Bart Fauser, Netherlands
Discussants Laura Rienzi, Italy
Rita Vassena, Spain
Catherine Racowsky, France
Basil Tarlatzis, Greece
Anja Pinborg, Denmark
Paul Pirtea, France

Questions to the panel

Embryology

  • Sperm separation and selection techniques: Do any really improve embryo quality and outcomes?
  • Should time-lapse imaging be implemented for all ART cycles?
  • Should genetic carrier screening be proposed systematically before ART?
  • Is non-invasive PGT-A still a promising approach?
  • Does the number of laser pulses impact embryo biopsy

Clinical aspects of IVF

  • Rescue IVM: Is it clinically relevant
  • Could artificial intelligence take over aspects of clinical management in ART?
  • Does recurrent implantation failure still exist as a distinct entity?
  • How can we decrease the cost of IVF, is natural IVF still useful in current practice?
  • Is preeclampsia truly more frequent after artificial embryo transfer cycles?
  • Mild ovarian stimulation for patients with diminished ovarian reserve: myth or reality?

 

15:00-16:30 OVULATION STIMULATION HALL A
Capsule Basic issues in ovulation induction are still not resolved
Chairpersons

15:00-15:25

Personalization of ovarian stimulation, do we need to base it on age and Markers of ORT
Frank Broekmans, Netherlands

15:25-15:30 Discussion
15:30-16:00

15:30
15:40
15:50

Debate: How important is the choice of gonadotropins and monitoring during stimulation?

It is important: Evangelos Makrakis, Greece
No better results were proven: Ioannis E. Messinis, Greece
Discussion

16:00-16:30

16:00
16:10
16:20

Debate: Mild ovarian stimulation for patients with diminished ovarian reserve (DOR): Myth or reality?

Higher doses will increase oocyte yield Frank Broekmans, Netherlands
Mild stimulation is the right way Paul Pirtea, France
Discussion

Skip to content